E Fund Management Co. Ltd. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,192 shares of the medical research company’s stock, valued at approximately $424,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $27,000. CrossGen Wealth LLC acquired a new position in shares of IQVIA in the fourth quarter valued at $28,000. Activest Wealth Management lifted its position in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the period. Finally, Financial Freedom LLC acquired a new stake in IQVIA during the first quarter worth $25,000. 89.62% of the stock is currently owned by institutional investors.
IQVIA Stock Up 3.0%
Shares of NYSE IQV opened at $256.66 on Friday. The stock has a market cap of $42.25 billion, a PE ratio of 31.84, a PEG ratio of 2.12 and a beta of 1.18. The business has a fifty day moving average of $211.74 and a two-hundred day moving average of $187.01. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $260.30. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.
IQVIA announced that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
Insider Activity
In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. 1.70% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the stock. Mizuho boosted their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Robert W. Baird raised their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Barclays reiterated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. JPMorgan Chase & Co. increased their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.
Get Our Latest Research Report on IQV
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Read More
- Five stocks we like better than IQVIA
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
